AATec Medical Announces Creation of Scientific Advisory Board
- Leading scientific and clinical experts, Prof. Dr. Ulrike Protzer, Prof. Dr. Jan Münch, and Dr. Gerhard Scheuch, join the newly established Scientific Advisory Board
- The Board’s collective expertise will support the advancement of AATec Medical’s recombinant alpha-1 antitrypsin (AAT) multi-product platform and pipeline
Munich, Germany – 10 October 2023 – AATec Medical GmbH (AATec), a biotech company developing a multi-product platform based on recombinant alpha-1 antitrypsin (AAT), today announced the creation of a Scientific Advisory Board.
Dr. Rüdiger Jankowsky, CEO commented: “We are honored to have such esteemed scientific experts joining AATec as advisors. Our Scientific Advisory Board is composed of pioneers in the fields of respiratory diseases, viral infections, and aerosolized drugs. Their extensive and diverse expertise will be invaluable as we continue to develop and advance our mission to fully unlock the therapeutic potential of AAT.”
The founding members of the Scientific Advisory Board are:
Prof. Dr. Ulrike Protzer
Prof. Dr. Ulrike Protzer, Director of the Institute of Virology at the Technical University of Munich and at Helmholtz Munich, Germany, is an internationally recognized expert in virus research and viral diseases. With her deep-rooted expertise in virology, she has been at the forefront of researching various viral infections and their impact on human health.
Prof. Dr. Jan Münch
Prof. Jan Münch, Director of the Institute of Molecular Virology at the University Medical Center in Ulm, Germany, is a leading expert in antiviral research. Amongst numerous highly ranked scientific publications, his team demonstrated effective inhibition of coronavirus entry into host cells by AAT, as published in Nature Communications.
Dr. Gerhard Scheuch
Dr. Gerhard Scheuch, CEO of GS BIO-INHALATION GmbH, is a seasoned biophysicist with an extensive background in aerosol medicine and pulmonary drug delivery. He has been instrumental in the development of various products for inhalation therapy and was appointed as a scientific advisor for the EMA. He previously served as a board member and president of the International Society for Aerosols in Medicine (ISAM). Dr. Scheuch co-founded several companies, including Inamed (acquired by Nuvsian in 2019), Activaero (acquired by Vectura in 2014), and Ventaleon.
Inflammatory diseases of the respiratory tract are increasing worldwide. Today’s lifestyle, demographics, virus infections, environmental effects and global migration contribute to this evolution. The creation of the Scientific Advisory Board underscores AATec’s commitment to unlocking the therapeutic potential of AAT, a human serine protease inhibitor with broad anti-inflammatory and antiviral effects to treat respiratory inflammatory diseases. Based on industrial-scale manufacturing of recombinant AAT in combination with innovations in inhalation technology, the company aims to provide differentiated and effective solutions for a range of respiratory diseases, including acute respiratory distress syndrome (ARDS), viral infections and allergic asthma.
AATec Medical GmbH is a biotechnology company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory diseases, virus infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-of-concept clinical trial with the first product candidate ATL-105 for inhaled application in respiratory diseases. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit www.aatec-medical.com and follow us on LinkedIn.
AATec Medical GmbH
Dr. Rüdiger Jankowsky, CEO
Katja Arnold, Julia von Hummel
Phone: +49 (0)89 2102280